Latest Intelligence on Genitourinary and Osteoporosis in Europe

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
Expert View
Expert View

World Congress on Osteoporosis highlights changing face of bone health

Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Vernalis/Endo: gain in menstrual migraine

New phase III data have confirmed previous results showing Vernalis and Endo's Frova to be an effective preventative treatment for menstrual migraine. This should pave the way for the migraine drug's approval in this additional indication. Anticipated in 2007, this approval is then expected to transform Frova's sales significantly.

Published By Datamonitor
08 May 2006
Expert View
Expert View

Urinary incontinence: treatments are improving, but unmet needs remain

Although the prevalence of urinary incontinence is high, treatment rates are low, in part because patients are often too embarrassed to seek help. No significant improvement in drug treatment has been made in 20 years; however, an easy to use gel which avoids the side effects and pill burden associated with currently available drugs, will soon be on the market.

Published By Datamonitor
01 Feb 2008
CommentWire
CommentWire

Tarsa: Novartis's fracture data do not bode well for Ostora

Novartis's SMC021 has failed to meet its main fracture reduction endpoint in a Phase III trial for osteoporosis. This is a setback for other firms aiming to stimulate the class's growth, such as Tarsa, which may now struggle to bring its pipeline drug Ostora to the market. Novartis is expected to discontinue the development of SMC021 and focus on more attractive targets for osteoporosis treatment.

Published By Datamonitor
16 Nov 2011
CommentWire
CommentWire

Servier: new Protelos data highlight shifting focus in osteoporosis research

As one of the lead sponsors of this year's World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, Servier presented new data for its dual action drug Protelos. Discussion of the therapy led on to the importance of companies using bone quality assessment, rather than relying on measurements of bone mineral density.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Sanofi-Aventis/Procter & Gamble: Actonel approved for men

Sanofi-Aventis and Procter & Gamble's Actonel has been given the green light for the treatment of male osteoporosis in the EU and US. This new indication for Actonel is good news for both companies, but the drug will still have to compete with Merck & Co's Fosamax, which is by far the biggest-selling therapy in the osteoporosis market.

Published By Datamonitor
18 Aug 2006
CommentWire
CommentWire

Roche/GSK: monthly formulation puts Boniva in pole position

The green light for Boniva sees it join Merck & Co's [MRK] Fosamax and Aventis's [SNY] Actonel as the newest member of the bisphosphonate family - a class of drugs that treat osteoporosis by increasing bone mineral density. Adherence to bisphosphonate regimens can be difficult for many patients, but Boniva's monthly formulation offers a major advance in overcoming this issue.

Published By Datamonitor
30 Mar 2005
CommentWire
CommentWire

Prolia: useful, but not quite revolutionary

Having received approval in both the US and Europe within the space of a few days, Datamonitor expects Amgen's osteoporosis antibody Prolia to achieve sales of over $850m across the seven major markets by 2019. However, despite its first-in-class status, Prolia is unlikely to revolutionize the current treatment algorithm, as existing unmet needs remain.

Published By Datamonitor
03 Jun 2010

« | 1 | 2 | 3 | 4 | » »|

No help is available.